Skip to main content
Clinical Trials/NCT03918356
NCT03918356
Completed
Not Applicable

Application of Electrical Impedance Myography (EIM) to Establish Muscle Impedance Parameters as a Potential Biomarker of Idiopathic Inflammatory Myopathies (IIMs)

Yale University1 site in 1 country5 target enrollmentJune 1, 2019

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Idiopathic Inflammatory Myopathies
Sponsor
Yale University
Enrollment
5
Locations
1
Primary Endpoint
IBM-Functional rating scale (IBM-FRS)
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

  1. To assess changes in impedance parameters in Idiopathic Inflammatory Myopathies (IIMs).
  2. To assess whether EIM parameters are reflective of disease severity, based on clinical outcome measures of IIMs.

Detailed Description

1. To assess changes in impedance parameters in Idiopathic Inflammatory Myopathies (IIMs) There are structural and compositional changes in muscles, such as edema, adipose infiltration, and/or atrophy, in IIMs. Electrical impedance myography (EIM) is sensitive to such changes. EIM parameters will be different when compared to healthy controls in IIMs. 2. To assess whether EIM parameters are reflective of disease severity, based on clinical outcome measures of IIMs. Clinical outcome measures reflect on disease severity which is an indirect measure of muscle involvement in IIMs. If EIM parameters correlate with clinical outcome measure, it would indirectly prove that EIM can reflect disease severity in IIMs

Registry
clinicaltrials.gov
Start Date
June 1, 2019
End Date
May 30, 2021
Last Updated
4 years ago
Study Type
Interventional
Study Design
Factorial
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • duration of weakness \>12 months.
  • ages 18 to 80 years old.
  • serum CK level no greater than 15 times the upper limit of normal.
  • quadriceps weakness \>hip flexor weakness and/or finger flexor weakness \>shoulder abduction weakness.
  • one or more of the following pathological findings:
  • endomysial inflammatory infiltrate.
  • rimmed vacuoles.
  • protein accumulation or 15-18 mm filaments.
  • DM/PM inclusion criteria:
  • ages 18 to 80

Exclusion Criteria

  • Patients with decompensated congestive heart failure
  • Patients with chronic kidney disease on hemodialysis
  • Patients with active cancer on chemotherapy or radiotherapy
  • Patients with severe disease who are already wheel chair bound

Outcomes

Primary Outcomes

IBM-Functional rating scale (IBM-FRS)

Time Frame: 2 years

This scale measure the limitations in daily life from IBM. It ask 10 questions regarding the activities of daily life and each question is scored between 0-4 (Where 4 means no difficulty and 0 means maximum difficulty). Total score can vary from 0-40, and 40 means no limitations in daily life from IBM.

Manual Muscle Testing Score

Time Frame: 2 years

This scale reflects on muscle strength. It is based on Medical Research Council scale for muscle power, where muscle strength can have a score of 0-5 (0 means no strength and 5 means full strength).Several muscles are examined in Manual Muscle Testing (MMT) and the total strength is reported as the sum of the Medical Research Council (MRC) muscles scale score of each muscles. Total MMT score for this study can range from 0-160, where 0 means no strength in any muscles and 160 means full strength in all the muscles examined.

Grip test

Time Frame: 2 years

A change in grip strength using a Jamar hand dynamometer to assess the grip strength in every participant. Best of three attempts will be used.

Myositis Intention to Treat Activities Index (MITAX)

Time Frame: 2 years

MITAX is a scale assessing the extra-muscular disease severity of myositis. It contains 24 questions covering 7 extra muscular organ systems. Each question is scored between 0-4, where 0 = not present, 1= improving, 2= same, 3= worse, and 4= new. This score is then converted to a final score ranging from A-E for each system based on a predefined scoring schema. Total MITAX score can range between 0 to 54.

Physician Global Assessment Score

Time Frame: 2 years

This is recorded on a 10-cm visual analog scale (VAS) by the physician at the time of evaluation. The score should reflect on the individual's appearance, medical history, physical examination, laboratory testing, and prescribed medical therapy. In this scale 0 means no evidence of disease related damage and 10 means extremely severe damage.

Get up and go test

Time Frame: 2 years

Time will be measured for a participant to stand up from a chair (using arms if necessary), walk 3 meters, turn around, return to the chair, and sit down. The better of two trials will be used.

Quality of Health and Well Being

Time Frame: 2 years

Short Form-36 (SF-36) is a measure of the global quality of health and well-being. The SF-36 is an eight-scaled score, which are the weighted sums of the questions in their corresponding section. Each scale can be transformed into a 0-100 scale. Lower score means more disability. SF-36 will be scored utilizing a standardized scoring manual. We will obtain a physical component summary scale and a mental component summary scale.

Six minute walk

Time Frame: 2 years

Distance walked in 6 minutes will be measured. This has been used as a primary and secondary outcome measures in several clinical trials in various neuromuscular disorders.

Study Sites (1)

Loading locations...

Similar Trials